Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion

Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...
Fintel on MSN

Jefferies Maintains Insulet (PODD) Buy Recommendation

Fintel reports that on November 6, 2025, Jefferies maintained coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation.